Lilly's Alimta patent gets court backing; Sanofi's Lantus may fend off artery-thickening a bit;

 @FiercePharma: Interested in the new GSK site at Philly's Navy Yard? 22 pics of construction in progress--via Philadelphia Business Journal. Gallery | Follow @FiercePharma

> Eli Lilly's ($LLY) exclusivity on the lung-cancer drug Alimta was confirmed by a U.S. appeals court; Teva Pharmaceutical Industries ($TEVA) had argued the patent was invalid. Report

> Sanofi's ($SNY) diabetes treatment Lantus appeared to help stave off atherosclerosis in certain patients, researchers said, as the French drugmaker looks for ways to differentiate the drug from potential rivals. Report

> After losing key U.S. partners, India's Claris Lifesciences says it will fly solo in the market and market drugs through its U.S. subsidiary. Report

> AstraZeneca ($AZN) agreed to pay $26 million to settle a lawsuit with the attorney general of South Carolina, who had sought to recover funds spent to treat patients using the antipsychotic drug Seroquel. Report

> India's foreign investment approval board cleared 8 acquisition proposals from foreign drug companies, some of which had been languishing since March. Report

Medical Device News

@FierceMedDev: It's a good day to be CardioDx. The company pulled in $58M in new financing. News | Follow @FierceMedDev

 @MarkHFierce: Cook Medical opens a new plant today in Illinois. Article | Follow @MarkHFierce

 @DamianFierce: The first wave of renal denervation devices have impressed docs in the EU. Report | Follow @DamianFierce

> CardioDx pulls in $58M to expand Dx commercial sales. News

> Interleukin Genetics' founder returns to CEO slot. Item

Biotech News

 @FierceBiotech: Analysis: For Eli Lilly's solanezumab, take 2 doesn't look so pretty. More | Follow @FierceBiotech

 @JohnCFierce: FDA wants a rewrite on Lemtrada app? Bit of an embarrassment for Genzyme and its overseers at Sanofi. Report | Follow @JohnCFierce

 @RyanMFierce: Ex-Google guys eye clinical trials with startup Flatiron. Story | Follow @RyanMFierce

> Promising T-DM1 clears PhIII cancer study and marches on to the FDA. Story

> Idenix plunges after FDA puts another hep C treatment on hold. News

> ESC Roundup: Head-to-head flop for Eli Lilly, PhII bonus for Novartis cardio drug. More

Biotech IT News

> Groups craft algorithms to rank drug contenders. Story

> Sanofi takes wisdom of crowd in social media blitz. Item

> Ex-Google guys eye clinical trials with startup Flatiron. News

> Amazon targets pharma R&D, others with new cloud storage. More

> Boehringer sets launch date for pharma's first social game on Facebook. Article

CRO News

> Chinese CRO Tigermed completes $80M IPO. Item

> West to open CMO facility in India. Story

> Pfizer backs out of generics deal with India's Claris. News

> PRA expands its Chinese presence as market swells. Article

> Researchers bristle at India's proposed trial reforms. Story

And Finally... Middle-management dissatisfaction is a global phenomenon: healthcare and pharma staffers in India say they're underpaid and dissatisfied on the job. Report

Suggested Articles

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.

AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.